Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.01 is in line with its 3-year average of 0.01, near the high end of its 3-year range (-0.05–0.01).
As of the fiscal period ended Tuesday, June 30, 2026. 29.65% below its 12-month average of 0.01.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.01.
DEBT TO EQUITY RATIO
0.01
DEBT TO EQUITY RATIO AVG TTM
0.01
DEBT TO EQUITY RATIO AVG 3Y
0.01
DEBT TO EQUITY RATIO AVG 5Y
N/A
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-29.65%
CURRENT VS 3Y AVG
-13.96%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.11
median of 689 covered companies
CURRENT VS SECTOR MEDIAN
-95.11%
vs the sector median at left
OnKure Therapeutics, Inc.
Market Cap
$102.46M
Debt to Equity Ratio
0.01
TTM Avg
0.01
3Y Avg
0.01
5Y Avg
N/A
Market Cap
$104.28M
Debt to Equity Ratio
0.01
TTM Avg
0.01
3Y Avg
0.01
5Y Avg
0.01
Market Cap
$104.68M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.03
5Y Avg
0.03
Market Cap
$105.27M
Debt to Equity Ratio
1.15
TTM Avg
0.59
3Y Avg
0.44
5Y Avg
0.41
Market Cap
$107.36M
Debt to Equity Ratio
0.27
TTM Avg
0.66
3Y Avg
0.63
5Y Avg
0.55
Market Cap
$107.73M
Debt to Equity Ratio
0.18
TTM Avg
0.22
3Y Avg
0.23
5Y Avg
0.18
Market Cap
$107.46M
Debt to Equity Ratio
0.04
TTM Avg
0.01
3Y Avg
0.26
5Y Avg
0.35
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| OnKure Therapeutics, Inc. (OKUR) | $102.46M | 0.01 | 0.01 | 0.01 | N/A |
| The Joint Corp. (JYNT)vs › | $102.71M | 0.13 | 0.09 | 0.27 | 0.46 |
| Anixa Biosciences, Inc. (ANIX)vs › | $104.28M | 0.01 | 0.01 | 0.01 | 0.01 |
| Polaryx Therapeutics, Inc. Common Stock (PLYX)vs › | $104.68M | 0.00 | 0.00 | 0.03 | 0.03 |
| Definitive Healthcare Corp. (DH)vs › | $105.27M | 1.15 | 0.59 | 0.44 | 0.41 |
| PolyPid Ltd. (PYPD)vs › | $99.61M | 0.29 | 0.75 | 1.29 | 0.77 |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $107.36M | 0.27 | 0.66 | 0.63 | 0.55 |
| Black Diamond Therapeutics, Inc. (BDTX)vs › | $107.73M | 0.18 | 0.22 | 0.23 | 0.18 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP)vs › | $107.46M | 0.04 | 0.01 | 0.26 | 0.35 |
| Korro Bio, Inc. (KRRO)vs › | $97.44M | 0.41 | 0.56 | 0.44 | 0.38 |
Debt/Equity
0.01
Current Ratio
26.75
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.01 |
| 2026-03-31 | 0.00 |
| 2025-12-31 | 0.01 |
| 2025-09-30 | 0.01 |
| 2025-06-30 | 0.01 |
| 2025-03-31 | 0.01 |
| 2024-12-31 | 0.01 |
| 2024-09-30 | 0.01 |
| 2024-06-30 | -0.05 |
| 2024-03-31 | -0.01 |
| 2023-12-31 | -0.01 |
| 2023-09-30 | 0.01 |
| 2023-06-30 | 0.01 |
| 2023-03-31 | 0.00 |
